Stem cell state and the epithelial-to-mesenchymal transition: Implications for cancer therapy

Journal of Clinical Pharmacology

Volumn 55, Issue 6, 2015, Pages 603-619

  Donnenberg, Vera S ^a,b   Donnenberg, Albert D ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

Cancer Stem Cell; Cancer Therapy; Epithelial to Mesenchymal Transition; Stem Cell State

Indexed keywords

ALDEHYDE DEHYDROGENASE; AZACITIDINE; B LYMPHOCYTE RECEPTOR; BCR ABL PROTEIN; BREAST CANCER RESISTANCE PROTEIN; CD133 ANTIGEN; CYCLOPHOSPHAMIDE; DINUTUXIMAB; EVEROLIMUS; IMATINIB; INTERLEUKIN 2; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 1; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 2; MULTIDRUG RESISTANCE PROTEIN 1; NILOTINIB; ONCOLYTIC VIRUS; PERFOSFAMIDE; PONATINIB; PV 701; REACTIVE OXYGEN METABOLITE; RETINOIC ACID; SONIDEGIB; STEM CELL FACTOR RECEPTOR; TELOMERASE; THY 1 ANTIGEN; TRABECTEDIN; TRASTUZUMAB; TRIPTOLIDE; VIMENTIN; VORINOSTAT; ANTINEOPLASTIC AGENT;

ACUTE MYELOBLASTIC LEUKEMIA; ADULT STEM CELL; BONE MARROW CELL; BREAST METASTASIS; CANCER STEM CELL; CANCER THERAPY; CARCINOGENICITY; CELL DIFFERENTIATION; CELL SPECIFICITY; DNA METHYLATION; ENZYME INHIBITION; EPIGENETICS; EPITHELIAL MESENCHYMAL TRANSITION; GASTROINTESTINAL STROMAL TUMOR; GENE DOSAGE; GENE EXPRESSION; GENE REARRANGEMENT; GENOMIC INSTABILITY; HEMATOPOIETIC STEM CELL; HUMAN; MEMBRANE PERMEABILITY; MULTIDRUG RESISTANCE; NONHUMAN; PHENOTYPE; REVIEW; RNA INTERFERENCE; TISSUE DISTRIBUTION; TUMOR MICROENVIRONMENT; TUMOR REGRESSION; UPREGULATION; ADULT; CELL TRANSFORMATION; CYTOLOGY; DISEASE COURSE; DRUG EFFECTS; MOLECULARLY TARGETED THERAPY; PATHOLOGY; PROCEDURES;

ADULT; ANTINEOPLASTIC AGENTS; CELL DIFFERENTIATION; CELL TRANSFORMATION, NEOPLASTIC; DISEASE PROGRESSION; EPITHELIAL-MESENCHYMAL TRANSITION; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASTIC STEM CELLS;

EID: 84928897029     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.486     Document Type: Review

References (160)

1. Fiala S., The cancer cell as a stem cell unable to differentiate. A theory of carcinogenesis. Neoplasma. 1968; 15 (6): 607-622.
2. Bonnet D, Dick JE., Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med. 1997; 3 (7): 730-737.
3. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF,. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A. 2003; 100 (7): 3983-3988.
4. Kelly PN, Dakic A, Adams JM, Nutt SL, Strasser A., Tumor growth need not be driven by rare cancer stem cells. Science. 2007; 317 (5836): 337.
5. Kern SE, Shibata D., The fuzzy math of solid tumor stem cells: a perspective. Cancer Res. 2007; 67 (19): 8985-8988.
6. Quintana E, Shackleton M, Sabel MS, Fullen DR, Johnson TM, Morrison SJ., Efficient tumour formation by single human melanoma cells. Nature. 2008; 456 (7222): 593-598.
7. Donnenberg AD, Hicks JB, Wigler M, Donnenberg VS., The cancer stem cell: Cell type or cell state? Cytometry A. 2013; 83A (1): 5-7.
8. Metcalf D., Concise review: hematopoietic stem cells and tissue stem cells: current concepts and unanswered questions. STEM CELLS. 2007; 25 (10): 2390-2395.
9. Till JE, McCulloch EA, Siminovitch L., A Stochastic model of stem cell proliferation, based on the growth of spleen colony-forming cells. Proc Natl Acad Sci U S A. 1964; 51: 29-36.
10. Till JE, McCulloch EA., A Direct Measurement of the radiation sensitivity of normal mouse bone marrow cells. Radiat Res. 1961; 14 (2): 213-222.
11. Bradley TR, Metcalf D, Sumner M, Stanley R., Characteristics of in vitro colony formation by cells from haemopoietic tissues. In Vitro. 1969; 4 (1): 22-35.
12. Strauss LC, Rowley SD, La Russa VF, Sharkis SJ, Stuart RK, Civin CI., Antigenic analysis of hematopoiesis. V. Characterization of My-10 antigen expression by normal lymphohematopoietic progenitor cells. Exp Hematol. 1986; 14 (9): 878-886.
13. Civin CI, Banquerigo ML, Strauss LC, Loken MR., Antigenic analysis of hematopoiesis. VI. Flow cytometric characterization of My-10-positive progenitor cells in normal human bone marrow. Exp Hematol. 1987; 15 (1): 10-17.
14. Civin CI, Strauss LC, Brovall C, Fackler MJ, Schwartz JF, Shaper JH., Antigenic analysis of hematopoiesis. III. A hematopoietic progenitor cell surface antigen defined by a monoclonal antibody raised against KG-1a cells. J Immunol. 1984; 133 (1): 157-165.
15. Spangrude GJ, Heimfeld S, Weissman IL., Purification and characterization of mouse hematopoietic stem cells. Science. 1988; 241 (4861): 58-62.
16. Berenson RJ, Andrews RG, Bensinger WI, et al. Antigen CD34+ marrow cells engraft lethally irradiated baboons. J Clin Invest. 1988; 81 (3): 951-955.
17. Berenson R, Bensinger W, Hill R, et al. Engraftment after infusion of CD34+ marrow cells in patients with breast cancer or neuroblastoma. Blood. 1991; 77 (8): 1717-1722.
18. Uckun FM., Regulation of human B-cell ontogeny. Blood. 1990; 76 (10): 1908-1923.
19. Civin CI, Almeida-Porada G, Lee MJ, Olweus J, Terstappen LW, Zanjani ED., Sustained, retransplantable, multilineage engraftment of highly purified adult human bone marrow stem cells in vivo. Blood. 1996; 88 (11): 4102-4109.
20. Goodell MA, Rosenzweig M, Kim H, et al. Dye efflux studies suggest that hematopoietic stem cells expressing low or undetectable levels of CD34 antigen exist in multiple species. Nat Med. 1997; 3 (12): 1337-1345.
21. Dick JE, Lapidot T., Biology of normal and acute myeloid leukemia stem cells. Int J Hematol. 2005; 82 (5): 389-396.
22. Craig W, Kay R, Cutler RL, Lansdorp PM., Expression of Thy-1 on human hematopoietic progenitor cells. The Journal of Exp Med. 1993; 177 (5): 1331-1342.
23. Berardi A, Wang A, Levine J, Lopez P, Scadden D., Functional isolation and characterization of human hematopoietic stem cells. Science. 1995; 267 (5194): 104-108.
24. Yin AH, Miraglia S, Zanjani ED, et al. AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood. 1997; 90 (12): 5002-5012.
25. Petriv OI, Kuchenbauer F, Delaney AD, et al. Comprehensive microRNA expression profiling of the hematopoietic hierarchy. Proc Natl Acad Sci U S A. 2010; 107 (35): 15443-15448.
26. Christensen JL, Weissman IL., Flk-2 is a marker in hematopoietic stem cell differentiation: A simple method to isolate long-term stem cells. Proc Natl Acad Sci U S A. 2001; 98 (25): 14541-14546.
27. Brown R, Herzig R, Wolff S, et al. High-dose etoposide and cyclophosphamide without bone marrow transplantation for resistant hematologic malignancy. Blood. 1990; 76 (3): 473-479.
28. Kastan M, Schlaffer E, Russo J, Colvin O, Civin C, Hilton J., Direct demonstration of elevated aldehyde dehydrogenase in human hematopoietic progenitor cells. Blood. 1990; 75 (10): 1947-1950.
29. Yoshida A, Rzhetsky A, Hsu LC, Chang C., Human aldehyde dehydrogenase gene family. Eur J Biochem. 1998; 251 (3): 549-557.
30. Jones RJ, Barber JP, Vala MS, et al. Assessment of aldehyde dehydrogenase in viable cells. Blood. 1995; 85 (10): 2742-2746.
31. Ginestier C, Hur MH, Charafe-Jauffret E, et al. ALDH1 Is a Marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell. 2007; 1 (5): 555-567.
32. Ito K, Hirao A, Arai F, et al. Regulation of oxidative stress by ATM is required for self-renewal of haematopoietic stem cells. Nature. 2004; 431 (7011): 997-1002.
33. Tothova Z, Kollipara R, Huntly BJ, et al. FoxOs are critical mediators of hematopoietic stem cell resistance to physiologic oxidative stress. Cell. 2007; 128 (2): 325-339.
34. Biedler JL, Riehm H., Cellular resistance to actinomycin D in Chinese hamster cells in vitro: cross-resistance, radioautographic, and cytogenetic studies. Cancer Res. 1970; 30 (4): 1174-1184.
35. Ling V, Thompson LH., Reduced permeability in CHO cells as a mechanism of resistance to colchicine. J Cell Physiol. 1974; 83 (1): 103-116.
36. Roninson IB, Abelson HT, Housman DE, Howell N, Varshavsky A., Amplification of specific DNA sequences correlates with multi-drug resistance in Chinese hamster cells. Nature. 1984; 309 (5969): 626-628.
37. Roninson IB, Chin JE, Choi KG, et al. Isolation of human mdr DNA sequences amplified in multidrug-resistant KB carcinoma cells. Proc Natl Acad Sci U S A. 1986; 83 (12): 4538-4542.
38. Gros P, Croop J, Roninson I, Varshavsky A, Housman DE., Isolation and characterization of DNA sequences amplified in multidrug-resistant hamster cells. Proc Natl Acad Sci U S A. 1986; 83 (2): 337-341.
39. Baines P, Visser JW., Analysis and separation of murine bone marrow stem cells by H33342 fluorescence-activated cell sorting. Exp Hematol. 1983; 11 (8): 701-708.
40. Mulder AH, Visser JW., Separation and functional analysis of bone marrow cells separated by rhodamine-123 fluorescence. Exp Hematol. 1987; 15 (1): 99-104.
41. Udomsakdi C, Eaves CJ, Sutherland HJ, Lansdorp PM., Separation of functionally distinct subpopulations of primitive human hematopoietic cells using rhodamine-123. Exp Hematol. 1991; 19 (5): 338-342.
42. Goodell MA, Brose K, Paradis G, Conner AS, Mulligan RC., Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J Exp Med. 1996; 183 (4): 1797-1806.
43. Mayle A, Luo M, Jeong M, Goodell MA., Flow cytometry analysis of murine hematopoietic stem cells. Cytometry A. 2013; 83 (1): 27-37.
44. Chaudhary PM, Mechetner EB, Roninson IB., Expression and activity of the multidrug resistance P-glycoprotein in human peripheral blood lymphocytes. Blood. 1992; 80 (11): 2735-2739.
45. Donnenberg VS, Burckart GJ, Griffith BP, Jain AB, Zeevi A, Donnenberg AD., P-glycoprotein (P-gp) is upregulated in peripheral T-cell subsets from solid organ transplant recipients. J Clin Pharmacol. 2001; 41 (12): 1271-1279.
46. Donnenberg VS, Donnenberg AD., Multiple drug resistance in cancer revisited: the cancer stem cell hypothesis. J Clin Pharmacol. 2005; 45 (8): 872-877.
47. Lum BL, Fisher GA, Brophy NA, et al. Clinical trials of modulation of multidrug resistance. Pharmacokinetic and pharmacodynamic considerations. Cancer. 1993; 72 (11 Suppl): 3502-3514.
48. van der Holt B, Löwenberg B, Burnett AK, et al. The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis. Blood. 2005; 106: 2646-2654.
49. Vaziri H, Schachter F, Uchida I, et al. Loss of telomeric DNA during aging of normal and trisomy 21 human lymphocytes. Am J Hum Genet. 1993; 52 (4): 661-667.
50. Kunimura C, Kikuchi K, Ahmed N, Shimizu A, Yasumoto S., Telomerase activity in a specific cell subset co-expressing integrinbeta1/EGFR but not p75NGFR/bcl2/integrin beta4 in normal human epithelial cells. Oncogene. 1998; 17 (2): 187-197.
51. Hiyama K, Hirai Y, Kyoizumi S, et al. Activation of telomerase in human lymphocytes and hematopoietic progenitor cells. J Immunol. 1995; 155 (8): 3711-3715.
52. Vaziri H, Dragowska W, Allsopp RC, Thomas TE, Harley CB, Lansdorp PM., Evidence for a mitotic clock in human hematopoietic stem cells: loss of telomeric DNA with age. Proc Natl Acad Sci U S A. 1994; 91 (21): 9857-9860.
53. Vardiman JW., Chronic myelogenous leukemia, BCR-ABL1+. Am J Clin Pathol. 2009; 132 (2): 250-260.
54. Fialkow PJ, Jacobson RJ, Papayannopoulou T., Chronic myelocytic leukemia: clonal origin in a stem cell common to the granulocyte, erythrocyte, platelet and monocyte/macrophage. Am J Med. 1977; 63 (1): 125-130.
55. Hochhaus A, O'Brien SG, Guilhot F, et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia. 2009; 23 (6): 1054-1061.
56. Gambacorti-Passerini CB, Gunby RH, Piazza R, Galietta A, Rostagno R, Scapozza L., Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias. Lancet Oncol. 2003; 4 (2): 75-85.
57. Graham SM, Jørgensen HG, Allan E, et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood. 2002; 99 (1): 319-325.
58. Sloma I, Jiang X, Eaves AC, Eaves CJ., Insights into the stem cells of chronic myeloid leukemia. Leukemia. 2010; 24 (11): 1823-1833.
59. Gerber JM, Qin L, Kowalski J, et al. Characterization of chronic myeloid leukemia stem cells. Am J Hematol. 2011; 86 (1): 31-37.
60. Hope KJ, Jin L, Dick JE., Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity. Nat Immunol. 2004; 5 (7): 738-743.
61. Hodes RJ, Hathcock KS, Weng NP., Telomeres in T and B cells. Nat Rev. 2002; 2 (9): 699-706.
62. Shao H, Xi L, Raffeld M, et al. Clonally related histiocytic/dendritic cell sarcoma and chronic lymphocytic leukemia/small lymphocytic lymphoma: a study of seven cases. Mod Pathol. 2011; 24 (11): 1421-1432.
63. Wagers AJ, Sherwood RI, Christensen JL, Weissman IL., Little evidence for developmental plasticity of adult hematopoietic stem cells. Science. 2002; 297 (5590): 2256-2259.
64. Stange Daniel E, Koo B-K, Huch M, et al. Differentiated Troy+ chief cells act as reserve stem cells to generate all lineages of the stomach epithelium. Cell. 2013; 155 (2): 357-368.
65. Tata PR, Mou H, Pardo-Saganta A, et al. Dedifferentiation of committed epithelial cells into stem cells in vivo. Nature. 2013; 503 (7475): 218-223.
66. Donnenberg VS, Donnenberg AD, Zimmerlin L, et al. Localization of CD44 and CD90 positive cells to the invasive front of breast tumors. Cytometry B Clin Cytom. 2010; 78 (5): 287-301.
67. Donnenberg VS, Landreneau RJ, Pfeifer ME, Donnenberg AD., Flow cytometric determination of stem/progenitor content in epithelial tissues: an example from nonsmall lung cancer and normal lung. Cytometry A. 2013; 83 (1): 141-149.
68. Potten CS, Owen G, Booth D., Intestinal stem cells protect their genome by selective segregation of template DNA strands. J Cell Sci. 2002; 115 (11): 2381-2388.
69. He XC, Zhang J, Tong W-G, et al. BMP signaling inhibits intestinal stem cell self-renewal through suppression of Wnt-[beta]-catenin signaling. Nat Genet. 2004; 36 (10): 1117-1121.
70. Roth KA, Hermiston ML, Gordon JA., Use of transgenic mice to infer the biological properties of small intestinal stem cells and to examine the lineage relationships of their descendants. Proc Natl Acad Sci U S A. 1991; 88: 9407-9411.
71. Vogel PM, Georgiade NG, Fetter BF, Vogel FS, McCarty KSJ., The correlation of histologic changes in the human breast with the menstrual cycle. Am J Pathol. 1981; 104 (1): 23-34.
72. Shackleton M, Vaillant F, Simpson KJ, et al. Generation of a functional mammary gland from a single stem cell. Nature. 2006; 439 (7072): 84-88.
73. Stingl J, Eaves CJ, Zandieh I, Emerman JT., Characterization of bipotent mammary epithelial progenitor cells in normal adult human breast tissue. Breast Cancer Res Treat. 2001; 67 (2): 93-109.
74. Ohyama M, Terunuma A, Tock CL, et al. Characterization and isolation of stem cell-enriched human hair follicle bulge cells. J Clin Invest. 2006; 116 (1): 249-260.
75. Zimmerlin L, Donnenberg VS, Pfeifer ME, et al. Stromal vascular progenitors in adult human adipose tissue. Cytometry A. 2010; 77A: 22-30.
76. Feisst V, Brooks AES, Chen C-JJ, Dunbar R., Characterisation of mesenchymal progenitor cell populations directly derived from human dermis. Stem Cells Devel. In press.
77. L, Donnenberg VS, Rubin JP, Donnenberg AD,. Mesenchymal markers on human adipose stem/progenitor cells. Cytometry A. 2013; 83A (1): 134-140.
78. Kusaba T, Lalli M, Kramann R, Kobayashi A, Humphreys BD., Differentiated kidney epithelial cells repair injured proximal tubule. Proc Natl Acad Sci U S A. 2014; 111 (4): 1527-1532.
79. Chen Y, Wong PP, Sjeklocha L, Steer CJ, Sahin MB., Mature hepatocytes exhibit unexpected plasticity by direct dedifferentiation into liver progenitor cells in culture. Hepatology. 2012; 55 (2): 563-574.
80. Yoo CB, Jones PA., Epigenetic therapy of cancer: past, present and future. Nat Rev Drug Discov. 2006; 5 (1): 37-50.
81. Factor Daniel C, Corradin O, Zentner Gabriel E, et al. Epigenomic comparison reveals activation of "seed" enhancers during transition from naive to primed pluripotency. Cell Stem Cell. 2014; 14 (6): 854-863.
82. Paul S, Knott JG., Epigenetic control of cell fate in mouse blastocysts: The role of covalent histone modifications and chromatin remodeling. Mol Reprod Dev. 2014; 81 (2): 171-182.
83. Burney MJ, Johnston C, Wong K-Y, et al. An epigenetic signature of developmental potential in neural stem cells and early neurons. Stem Cells. 2013; 31 (9): 1868-1880.
84. Lee BM, Mahadevan LC., Stability of histone modifications across mammalian genomes: Implications for "epigenetic" marking. J Cell Biochem. 2009; 108 (1): 22-34.
85. Wilmut I, Schnieke AE, McWhir J, Kind AJ, Campbell KHS., Viable offspring derived from fetal and adult mammalian cells. Nature. 1997; 385 (6619): 810-813.
86. Takahashi K, Tanabe K, Ohnuki M, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007; 131 (5): 861-872.
87. Yu J, Vodyanik MA, Smuga-Otto K, et al. Induced pluripotent stem cell lines derived from human somatic cells. Science. 2007; 318 (5858): 1917-1920.
88. Abad M, Mosteiro L, Pantoja C, et al. Reprogramming in vivo produces teratomas and iPS cells with totipotency features. Nature. 2013; 502 (7471): 340-345.
89. Fitchett JE, Hay ED., Medial edge epithelium transforms to mesenchyme after embryonic palatal shelves fuse. Dev Biol. 1989; 131 (2): 455-474.
90. Chagraoui J, Lepage-Noll A, Anjo A, Uzan G, Charbord P., Fetal liver stroma consists of cells in epithelial-to-mesenchymal transition. Blood. 2003; 101 (8): 2973-2982.
91. Rothenpieler UW, Dressler GR., Pax-2 is required for mesenchyme-to-epithelium conversion during kidney development. Development. 1993; 119 (3): 711-720.
92. Kalluri R, Weinberg RA., The basics of epithelial-mesenchymal transition. J Clin Invest. 2009; 119 (6): 1420-1428.
93. Yang J, Mani SA, Donaher JL, et al. Twist, a Master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell. 2004; 117 (7): 927-939.
94. Zagni C, Chiacchio U, Rescifina A., Histone methyltransferase inhibitors: novel epigenetic agents for cancer treatment. Curr Med Chem. 2013; 20 (2): 167-185.
95. Taube JH, Malouf GG, Lu E, et al. Epigenetic silencing of microRNA-203 is required for EMT and cancer stem cell properties. Sci Rep. 2013; 3: 2687.
96. Mitra A, Satelli A, Xia X, Cutrera J, Mishra L, Li S., Cell-surface Vimentin: a mislocalized protein for isolating csVimentin+CD133- novel stem-like hepatocellular carcinoma cells expressing EMT markers. Int J Cancer. 2014 doi: 10.1002/ijc.29382
97. Jing Y-Y, Han Z-P, Sun K, et al. Toll-like receptor 4 signaling promotes epithelial-mesenchymal transition in human hepatocellular carcinoma induced by lipopolysaccharide. BMC Med. 2012; 10 (1): 98.
98. Liu W-T, Jing Y-Y, Yu G-f, et al. Toll like receptor 4 facilitates invasion and migration as a cancer stem cell marker in hepatocellular carcinoma. Cancer Lett. 2015; 358 (2): 136-143.
99. Satelli A, Mitra A, Brownlee Z, et al. Epithelial-Mesenchymal transitioned circulating tumor cells capture for detecting tumor progression. Clin Cancer Res. 2015; 21 (4): 899-906.
100. Satelli A, Mitra A, Cutrera JJ, et al. Universal marker and detection tool for human sarcoma circulating tumor cells. Cancer Res. 2014; 74 (6): 1645-1650.
101. Quintana E, Shackleton M, Foster HR, et al. Phenotypic heterogeneity among tumorigenic melanoma cells from patients that is reversible and not hierarchically organized. Cancer Cell. 2010; 18 (5): 510-523.
102. Hoek KS, Goding CR., Cancer stem cells versus phenotype-switching in melanoma. Pigment Cell Melanoma Res. 2010; 23 (6): 746-759.
103. Saez-Ayala M, Montenegro MF, Sanchez-Del Campo L, et al. Directed phenotype switching as an effective antimelanoma strategy. Cancer Cell. 2013; 24 (1): 105-119.
104. Banerji S, Cibulskis K, Rangel-Escareno C, et al. Sequence analysis of mutations and translocations across breast cancer subtypes. Nature. 2012; 486 (7403): 405-409.
105. Ince TA, Richardson AL, Bell GW, et al. Transformation of different human breast epithelial cell types leads to distinct tumor phenotypes. Cancer Cell. 2007; 12 (2): 160-170.
106. Lu H, Clauser KR, Tam WL, et al. A breast cancer stem cell niche supported by juxtacrine signaling from monocytes and macrophages. Nat Biotechnol. 2014; 16 (1): 1105-1117.
107. Donnenberg AD, Zimmerlin L, Landreneau RJ, Luketich JD, Donnenberg VS., KIT (CD117) expression in a subset of non-small cell lung carcinoma (NSCLC) patients. PloS One. 2012; 7 (12): 1-11.
108. Kelloff GJ, Sigman CC., Cancer biomarkers: selecting the right drug for the right patient. Nat Rev Drug Discov. 2012; 11 (3): 201-214.
109. Shoemaker RH., The NCI60 human tumour cell line anticancer drug screen. Nat Rev Cancer. 2006; 6 (10): 813-823.
110. Burdach S., Molecular precision chemotherapy: overcoming resistance to targeted therapies? Clin Cancer Res. 2014; 20 (5): 1064-1066.
111. Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006; 355 (23): 2408-2417.
112. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002; 347 (7): 472-480.
113. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005; 353 (16): 1659-1672.
114. Moja L, Tagliabue L, Balduzzi S, et al. Trastuzumab containing regimens for early breast cancer. Cochrane Database Systematic Rev. 2012; 4:Cd006243.
115. Pohlmann PR, Mayer IA, Mernaugh R., Resistance to trastuzumab in breast cancer. Clin Cancer Res. 2009; 15 (24): 7479-7491.
116. Grohar PJ, Segars LE, Yeung C, et al. Dual targeting of EWS-FLI1 activity and the associated DNA damage response with trabectedin and SN38 synergistically inhibits Ewing sarcoma cell growth. Clin Cancer Res. 2014; 20 (5): 1190-1203.
117. Ruden M, Puri N., Novel anticancer therapeutics targeting telomerase. Cancer Treat Rev. 2013; 39 (5): 444-456.
118. Shay JW, Wright WE., Telomeres and telomerase in normal and cancer stem cells. FEBS Lett. 2010; 584 (17): 3819-3825.
119. Pecot CV, Calin GA, Coleman RL, Lopez-Berestein G, Sood AK., RNA interference in the clinic: challenges and future directions. Nat Rev Cancer. 2011; 11 (1): 59-67.
120. Tabernero J, Shapiro GI, LoRusso PM, et al. First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement. Cancer Discov. 2013; 3 (4): 406-417.
121. Yang D, Sun Y, Hu L, et al. Integrated analyses identify a master microRNA regulatory network for the mesenchymal subtype in serous ovarian cancer. Cancer Cell. 2013; 23 (2): 186-199.
122. Katz TA, Huang Y, Davidson NE, Jankowitz RC., Epigenetic reprogramming in breast cancer: from new targets to new therapies. Ann Med. 2014; 46 (6): 397-408.
123. Akhtar-Zaidi B, Cowper-Sallari R, Corradin O, et al. Epigenomic enhancer profiling defines a signature of colon cancer. Science. 2012; 336 (6082): 736-739.
124. Grignani F, De Matteis S, Nervi C, et al. Fusion proteins of the retinoic acid receptor-[alpha] recruit histone deacetylase in promyelocytic leukaemia. Nature. 1998; 391 (6669): 815-818.
125. Tallman MS, Andersen JW, Schiffer CA, et al. All-trans-retinoic acid in acute promyelocytic leukemia. N Engl J Med. 1997; 337 (15): 1021-1028.
126. Scales SJ, de Sauvage FJ., Mechanisms of Hedgehog pathway activation in cancer and implications for therapy. Trends Pharmacol Sci. 2009; 30 (6): 303-312.
127. Amakye D, Jagani Z, Dorsch M., Unraveling the therapeutic potential of the Hedgehog pathway in cancer. Nat Med. 2013; 19 (11): 1410-1422.
128. Kwon H-Y, Kim S-J, Kim C-H, et al. Triptolide downregulates human GD3 synthase (hST8Sia I) gene expression in SK-MEL-2 human melanoma cells. Exp Mol Med. 2010; 42: 849-855.
129. Chugh R, Sangwan V, Patil SP, et al. A preclinical evaluation of minnelide as a therapeutic agent against pancreatic cancer. Sci Transl Med. 2012; 4 (156):156ra139.
130. Liu L, Salnikov AV, Bauer N, et al. Triptolide reverses hypoxia-induced epithelial-mesenchymal transition and stem-like features in pancreatic cancer by NF-κB downregulation. Int J Cancer. 2014; 134 (10): 2489-2503.
131. Sangwan V, Saluja AK., Mechanism of action of the anti-cancer agent, triptolide. In:, Sarkar FH, ed. Nutraceuticals and Cancer. Dordrecht Heidelberg, London, New York: Springer; 2012: 135-150.
132. Yu AL, Gilman AL, Ozkaynak MF, et al. Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma. N Engl J Med. 2010; 363 (14): 1324-1334.
133. Sarkar TR, Battula VL, Werden SJ, et al. GD3 synthase regulates epithelial-mesenchymal transition and metastasis in breast cancer. Oncogene. 2014; 0.
134. Pecora AL, Rizvi N, Cohen GI, et al. Phase I Trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers. J Clin Oncol. 2002; 20 (9): 2251-2266.
135. Lichty BD, Breitbach CJ, Stojdl DF, Bell JC., Going viral with cancer immunotherapy. Nat Rev Cancer. 2014; 14 (8): 559-567.
136. Albelda SM, Thorne SH., Giving oncolytic vaccinia virus more BiTE. Mol Ther. 2014; 22 (1): 6-8.
137. Dienstmann R, Rodon J, Serra V, Tabernero J., Picking the point of inhibition: a comparative review of PI3K/AKT/mTOR pathway inhibitors. Mol Cancer Ther. 2014; 13 (5): 1021-1031.
138. Ellard SL, Clemons M, Gelmon KA, et al. Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND.163. J Clin Oncol. 2009; 27 (27): 4536-4541.
139. Gulhati P, Bowen KA, Liu J, et al. mTORC1 and mTORC2 regulate EMT, motility, and metastasis of colorectal cancer via RhoA and Rac1 signaling pathways. Cancer Res. 2011; 71 (9): 3246-3256.
140. Rothwell PM, Wilson M, Price JF, Belch JFF, Meade TW, Mehta Z., Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet. 2012; 379 (9826): 1591-1601.
141. Algra AM, Rothwell PM., Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials. Lancet Oncol. 2012; 13 (5): 518-527.
142. Rothwell PM, Price JF, Fowkes FG, et al. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet. 2012; 379 (9826): 1602-1612.
143. Krug LM, Crapanzano JP, Azzoli CG, et al. Imatinib mesylate lacks activity in small cell lung carcinoma expressing c-kit protein. Cancer. 2005; 103 (10): 2128-2131.
144. Kajstura J, Rota M, Hall SR, et al. Evidence for human lung stem cells. N Engl J Med. 2011; 364 (19): 1795-1806.
145. Martens JHA, Brinkman AB, Simmer F, et al. PML-RARα/RXR alters the epigenetic landscape in acute promyelocytic leukemia. Cancer Cell. 2010; 17 (2): 173-185.
146. Fetahu IS, Höbaus J, Kállay E., Vitamin D and the epigenome. Front Physiol. 2014; 5: 164.
147. Valeri N, Vannini I, Fanini F, Calore F, Adair B, Fabbri M., Epigenetics, miRNAs, and human cancer: a new chapter in human gene regulation. Mamm Genome. 2009; 20 (9-10): 573-580.
148. Omenetti A, Porrello A, Jung Y, et al. Hedgehog signaling regulates epithelial-mesenchymal transition during biliary fibrosis in rodents and humans. J Clin Invest. 2008; 118 (10): 3331-3342.
149. Goldbach-Mansky R, Wilson M, Fleischmann R, et al. Comparison of Tripterygium wilfordii hook f versus sulfasalazine in the treatment of rheumatoid arthritis: a randomized trial. Ann Intern Med. 2009; 151 (4): 229-240.
150. Masferrer JL, Leahy KM, Koki AT, et al. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res. 2000; 60 (5): 1306-1311.
151. Erpenbeck L, Schön MP., Deadly allies: the fatal interplay between platelets and metastasizing cancer cells.
152. Donnenberg VS, Landreneau RJ, Donnenberg AD., Tumorigenic stem and progenitor cells: implications for the therapeutic index of anti-cancer agents. J Control Release. 2007; 122 (3): 385-391.
153. Baer C, Squadrito ML, Iruela-Arispe ML, De Palma M., Reciprocal interactions between endothelial cells and macrophages in angiogenic vascular niches. Exp Cell Res. 2013; 319 (11): 1626-1634.
154. Larue L, Bellacosa A., Epithelial-mesenchymal transition in development and cancer: role of phosphatidylinositol 3[prime] kinase//AKT pathways. Oncogene. 0000; 24 (50): 7443-7454.
155. Onoyama M, Kitadai Y, Tanaka Y, et al. Combining molecular targeted drugs to inhibit both cancer cells and activated stromal cells in gastric cancer. Neoplasia. 2013; 15 (12): 1391-1399.
156. Karnoub AE, Dash AB, Vo AP, et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature. 2007; 449 (7162): 557-563.
157. El-Haibi CP, Bell GW, Zhang J, et al. Critical role for lysyl oxidase in mesenchymal stem cell-driven breast cancer malignancy. Proc Natl Acad Sci U S A. 2012; 109 (43): 17460-17465.
158. Kolb H, Schattenberg A, Goldman J, et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients.
159. Porter DL, Levine BL, Kalos M, Bagg A, June CH., Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med. 2011; 365 (8): 725-733.
160. Thakur A, Lum LG., Cancer therapy with bispecific antibodies: clinical experience. Curr Opin Mol Ther. 2010; 12 (3): 340-349.